Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6157827 | 0.94 | CASP1 (0.43) | KMT2AHPGDALDH1A1CASP1TSHR | |
| SCHEMBL6157985 | 0.86 | CASP3 (0.41) | CASP1 | |
| SCHEMBL6160437 | 0.85 | CASP1 (0.52) | CASP1MTNR1AMTNR1B | |
| SCHEMBL6158900 | 0.83 | CASP1 (0.38) | KMT2AALDH1A1CASP1MAPT | |
| SCHEMBL6161919 | 0.80 | CASP1 (0.47) | KMT2AHPGDCASP1LMNA | |
| SCHEMBL6161964 | 0.79 | CASP1 (0.54) | KMT2AHPGDALDH1A1CASP1CYP2C19 | |
| SCHEMBL6158761 | 0.78 | CASP1 (0.38) | KMT2AALDH1A1CASP1TSHRMAPT | |
| SCHEMBL7487986 | 0.78 | CASP1 (0.55) | CASP1 | |
| SCHEMBL6157421 | 0.77 | CASP1 (0.41) | KMT2ACASP1MTNR1AMTNR1BMAPT | |
| SCHEMBL6158570 | 0.74 | CASP1 (0.49) | KMT2AHPGDCASP1MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1082127-B1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | claimed |
| EP-1082127-B1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-1075467-B1 | PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | EP | disclosed |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-10-24 | — | — | US | disclosed |
| US-6444696-B1 | 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) LLC | 2002-09-03 | — | — | US | disclosed |
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | GOLDSTEIN DAVID MICHAEL (US) | 2002-08-01 | — | — | US | disclosed |
| US-6376527-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6316466-B1 | Pyrazole derivatives P-38 MAP kinase inhibitors | SYNTEX (U.S.A.) LLC | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103245-A1 | Pyrazole derivatives P38 MAP kinase inhibitors | MAPK1, MAPK8, MAPKAPK2 | KMT2A 3772/4885HPGD 644/4885ALDH1A1 1667/4885 |
| US-20020156114-A1 | Pyrazole derivatives - p38 MAP kinase inhibitors | MAPK1, MAPK8, MAP3K8 | KMT2A 3828/4885HPGD 776/4885ALDH1A1 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.